Cerecor Inc. (NASDAQ:CERC) moved 1.57% to recent value of $2.58. The stock transacted 113673 shares during most recent day however it has an average volume of 120.38K shares. It spotted trading -58.32% off 52-week high price. On the other end, the stock has been noted 69.74% away from the low price over the last 52-weeks.
On April 24, 2020, Cerecor Inc. (NASDAQ:CERC) a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, disclosed that Dr. Sol J. Barer has been appointed as the Chairman of the Board as Dr. Simon Pedder steps down as Executive Chairman. Additionally, Dr. Suzanne Bruhn and Mr. Joseph Miller have been appointed as Directors to the Company’s Board.
We are extremely pleased to welcome Dr. Barer as our Chairman of the Board. Sol is an icon in the biopharmaceutical industry with decades of hands-on experience building, leading and financing companies based on innovative science and technologies that have potential to address significant unmet patient needs. The additions of Dr. Bruhn and Mr. Miller further strengthen our Board with their deep insights from years of successful biopharmaceutical experience. We look forward to their leadership, insights and experience to help guide our organization and the development of our near-term clinical pipeline in rare pediatric and orphan diseases, stated Mike Cola, CEO of Cerecor. Additionally, we would like to thank Dr. Pedder for his service as Executive Chairman, who will stay on the Board until our shareholders meeting, and his willingness afterwards, to stay on in an advisory role to the Board.
Dr. Barer has served on the Company’s Board since February 2020. Dr. Barer spent most of his professional career with the Celgene Corporation where he was the Founder, CEO and Chairman. Dr. Barer serves as Chairman of the Board of Teva Pharmaceuticals, Centrexion Therapeutics Corporation, and NexImmune and is the Lead Director of ContraFect. Dr. Barer received his Ph.D. in organic and physical chemistry from Rutgers University and his B.S. in chemistry from Brooklyn College of the City University of New York.
I am thrilled to take on the role as Chairman of the Board, said Dr. Barer. I look forward to applying my expertise and detailed knowledge of the business to help guide the organization. It is an exciting time for Cerecor as the Company works to accelerate its pipeline of six near-term, novel clinical assets to help the patients and families associated with rare pediatric and orphan diseases.
Its earnings per share (EPS) expected to touch remained 64.30% for this year.
The company has 59.55M of outstanding shares and 49.37M shares were floated in the market. According to the most recent quarter its current ratio was 1.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 3.01% from the mean of 20 days, -8.88% from mean of 50 days SMA and performed -28.15% from mean of 200 days price. Company’s performance for the week was -7.86%, -2.27% for month and YTD performance remained -52.13%.